GPR65 Inactivation in Tumor Cells Drives Antigen-Independent CAR T-cell Resistance via Macrophage Remodeling

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise for hematologic malignancies.
• Understanding resistance mechanisms is crucial for optimizing CAR T-cell therapy efficacy.
• The tumor microenvironment (TME) plays a significant role in CAR T-cell function.

Purpose of the Study:

• To identify key determinants of response to CAR T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL).
• To explore strategies for overcoming resistance to CAR T-cell therapy.
• To investigate the role of the TME in modulating CAR T-cell therapy outcomes.

Main Methods:

• Analysis of G protein-coupled receptor 65 (GPR65) expression in B-ALL patient samples.
• In vitro and in vivo models of CAR T-cell therapy resistance.
• Investigating the impact of VEGFA and macrophage modulation on CAR T-cell activity.

Main Results:

• GPR65 expression levels are a critical determinant of CAR T-cell therapy response in B-ALL.
• Absence of GPR65 is associated with resistance to CAR T-cell therapy.
• Targeting VEGFA or host macrophages can enhance CAR T-cell efficacy in a GPR65-dependent manner.

Conclusions:

• GPR65 is a potential biomarker for predicting CAR T-cell therapy response in B-ALL.
• Modulating the TME by targeting VEGFA or macrophages represents a viable strategy to improve CAR T-cell therapy outcomes.
• These findings offer new therapeutic avenues for patients with hematologic malignancies resistant to current treatments.